BACKGROUND: New targeted cancer treatments acting against growth factor receptors such as the epidermal growth factor receptor (EGFR) necessitate selecting patients for treatment with these drugs. Besides carcinomas, soft tissue sarcomas (STS) express EGFR and might thereby be a promising target for this new therapeutic strategy. OBJECTIVE: To test and compare different EGFR antibodies to determine the frequency of EGFR expression in STS. METHODS: 302 consecutive specimens of STS were examined using the tissue microarray technique. EGFR expression levels were assessed by immunohistochemistry using five different commercially available antibodies. Gene amplification status was measured by fluorescence in situ hybridisation (FISH). Immunoreactivity and amplification status were correlated with clinicopathological features and follow up data available in 163 cases. RESULTS: EGFR expression frequency ranged between 0.3% and 52.9%, depending on the antibody and scoring method used. In all, 3.5% of the tumours showed egfr gene amplification by FISH, which correlated with EGFR expression for three antibodies. Only one antibody had independent prognostic value in multivariate analysis and correlated with an unfavourable outcome; egfr gene amplification status showed no correlation with clinical features. CONCLUSIONS: Frequency of EGFR immunopositivity in STS strongly depends on the antibody used, and only one of five antibodies tested predicted an unfavourable clinical outcome. This indicates that choice of primary antibody and scoring system have a substantial impact on the determination of EGFR immunoreactivity.
BACKGROUND: New targeted cancer treatments acting against growth factor receptors such as the epidermal growth factor receptor (EGFR) necessitate selecting patients for treatment with these drugs. Besides carcinomas, soft tissue sarcomas (STS) express EGFR and might thereby be a promising target for this new therapeutic strategy. OBJECTIVE: To test and compare different EGFR antibodies to determine the frequency of EGFR expression in STS. METHODS: 302 consecutive specimens of STS were examined using the tissue microarray technique. EGFR expression levels were assessed by immunohistochemistry using five different commercially available antibodies. Gene amplification status was measured by fluorescence in situ hybridisation (FISH). Immunoreactivity and amplification status were correlated with clinicopathological features and follow up data available in 163 cases. RESULTS:EGFR expression frequency ranged between 0.3% and 52.9%, depending on the antibody and scoring method used. In all, 3.5% of the tumours showed egfr gene amplification by FISH, which correlated with EGFR expression for three antibodies. Only one antibody had independent prognostic value in multivariate analysis and correlated with an unfavourable outcome; egfr gene amplification status showed no correlation with clinical features. CONCLUSIONS: Frequency of EGFR immunopositivity in STS strongly depends on the antibody used, and only one of five antibodies tested predicted an unfavourable clinical outcome. This indicates that choice of primary antibody and scoring system have a substantial impact on the determination of EGFR immunoreactivity.
Authors: Violetta Barbashina; Joseph Benevenia; Hana Aviv; James Tsai; Francis Patterson; Seena Aisner; Stanley Cohen; Helen Fernandes; Joan Skurnick; Meera Hameed Journal: J Cancer Res Clin Oncol Date: 2002-10-29 Impact factor: 4.553
Authors: Torsten O Nielsen; Forrest D Hsu; John X O'Connell; C Blake Gilks; Poul H B Sorensen; Sabine Linn; Robert B West; Chih Long Liu; David Botstein; Patrick O Brown; Matt van de Rijn Journal: Am J Pathol Date: 2003-10 Impact factor: 4.307
Authors: Elena Tamborini; Lorena Bonadiman; Angela Greco; Alessandro Gronchi; Carla Riva; Rossella Bertulli; Paolo G Casali; Marco A Pierotti; Silvana Pilotti Journal: Clin Cancer Res Date: 2004-02-01 Impact factor: 12.531
Authors: Ernest C Borden; Laurence H Baker; Robert S Bell; Vivien Bramwell; George D Demetri; Burton L Eisenberg; Christopher D M Fletcher; Jonathan A Fletcher; Marc Ladanyi; Paul Meltzer; Brian O'Sullivan; David R Parkinson; Peter W T Pisters; Scott Saxman; Samuel Singer; Murali Sundaram; Allan T van Oosterom; Jaap Verweij; Jill Waalen; Sharon W Weiss; Murray F Brennan Journal: Clin Cancer Res Date: 2003-06 Impact factor: 12.531
Authors: Kimberley S Samkoe; Hira S Sardar; Brent D Bates; Niki N Tselepidakis; Jason R Gunn; Kevin A Hoffer-Hawlik; Joachim Feldwisch; Brian W Pogue; Keith D Paulsen; Eric R Henderson Journal: J Surg Oncol Date: 2019-04-04 Impact factor: 3.454
Authors: Hira Shahzad Sardar; Qais Zai; Jason Gunn; Brian Pogue; Keith Paulsen; Kimberley Samkoe; Eric Henderson Journal: Proc SPIE Int Soc Opt Eng Date: 2019-03-07
Authors: Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-17 Impact factor: 9.236
Authors: F Molinari; V Martin; P Saletti; S De Dosso; A Spitale; A Camponovo; A Bordoni; S Crippa; L Mazzucchelli; M Frattini Journal: Br J Cancer Date: 2009-03-17 Impact factor: 7.640